Home / Industry Updates / The Monitor
The I2CAN Monitor
A free monthly review of aesthetic medicine in India and worldwide. First Tuesday of the month, six to eight minutes to read, every claim attributed.
Most of what circulates in this field each month is a press release with the header removed. The Monitor exists because somebody has to read the primary sources and say plainly what they do and do not show, including the months when the answer is that nothing much happened.
Every issue keeps the same seven sections in the same order, so you can skip to the part you care about. Every issue ends with a sources block listing every URL cited. That block looks like clutter during a build and it is the first thing that gets cut. It is not clutter.
What is in every issue
-
01
The Opening Read 150-220 words
What one member of faculty thinks mattered most this month, and why. Signed.
-
02
India Desk Three to four items
What happened here. Regulation, devices reaching the market, professional bodies, training.
-
03
The Wider Field Three items
What happened elsewhere that will reach India, and roughly when.
-
04
The Technical Note 300-400 words
The flagship. One procedure, one device or one molecule, examined properly. Carries a mandatory limitations paragraph written as properties of the study.
-
05
Safety Note 200-280 words
What went wrong somewhere, and what it implies for practice here. Signed by a named clinician.
-
06
From the Journals Four to six items
Always at least one Indian-authored paper. Always at least one null finding.
-
07
The Patient Shift 350-450 words plus a data box
What patients are asking for that they were not asking for a year ago.
Issue one
Issue one is in preparation. It will not publish until a named member of faculty has signed the Technical Note and the Safety Note, because nothing clinical publishes here unsigned. When it is ready it will appear at a permanent URL of its own, which will never be reused or redirected.
There is no archive on this page yet because there is nothing in it. An empty section is left out rather than labelled "coming soon".
The rules we publish under.
These are not aspirations. They are the constraints that make everything else on these pages worth reading, and the reason a thin month produces a shorter issue rather than a padded one.
Every factual claim names its source
If a number cannot be attributed, it does not run. Not even hedged.
Nothing clinical publishes unsigned
Clinical content carries an individual faculty byline and that named person signs off its accuracy. Industry commentary is written by the founder, who does not sign clinical content.
Every issue carries something that did not work
At least one null finding per issue. A publication that only reports success is an advertisement.
We name no competitor
Favourably or otherwise. We will disagree with a trend. We will not disparage an institution.
No pricing anywhere
Not course fees, not procedure fees, not device costs.
Where the data is American, we say so
India has no registry for this field, and we will not dress someone else's numbers as ours.
A thin month makes a shorter issue
If a category produced nothing worth reporting, it is left out rather than padded.
Limitations are stated as properties of the study
Thirty-two patients, three months, a single centre. Not as our hesitations about it.